A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens

Oncologist

Volumn 13, Issue 4, 2008, Pages 467-473

  Ray Coquard, Isabelle ^a   Le Cesne, Axel ^b   Whelan, Jeremy S ^c   Schoffski, Patrick ^d   Bui, Binh N ^e   Verweij, Jaap ^f   Marreaud, Sandrine ^g   Van Glabbeke, Martine ^g   Hogendoorn, Pancras ^h   Blay, Jean Yves ^a  

^a CENTRE LÉON BÉRARD   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e INSTITUT BERGONIÉ   (France)

^f UZ and Erasmus   (Netherlands)

^g EORTC DATA CENTER   (Belgium)

^h LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Expression microarrays; Gefitinib; HER 1; Sarcoma; Synovial sarcoma

Indexed keywords

DOXORUBICIN; GEFITINIB; IFOSFAMIDE; PAZOPANIB; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GENE TRANSLOCATION; HEADACHE; HUMAN; HYPOXIA; LETHARGY; LIFE EXPECTANCY; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; ONCOGENE NEU; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SKIN TOXICITY; SOFT TISSUE METASTASIS; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DISEASE PROGRESSION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SARCOMA, SYNOVIAL; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 43549083034     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0065     Document Type: Article

References (41)

1. Clark MA, Fisher C, Judson I et al. Soft-tissue sarcomas in adults. N Engl J Med 2005;353:701-711.
2. Hogendoorn PC, Collin F, Daugaard S et al.; Pathology and Biology Subcommittee of the EORTC Soft Tissue and Bone Sarcoma Group. Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment. Eur J Cancer 2004;40:1644-1654.
3. Clark J, Rocques PJ, Crew AJ et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p112;q11.2) translocation found in human synovial sarcoma. Nat Genet 1994;7:502-508.
4. Crew AJ, Clark J, Fisher C et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J 1995;14:2333-2340.
5. Trassard M, Le Doussal V, Hacene K et al. Prognostic factors in localized primary synovial sarcoma: A multicenter study of 128 adult patients. J Clin Oncol 2001;19:525-534.
6. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997;350:1647-1654.
7. Nielsen OS, Blay JY, Judson IR et al. Metastatic soft tissue sarcoma in adults. Prognosis and treatment options. Am J Cancer 2003;2:1-12.
8. Van Glabbeke M, van Oosterom AT, Oosterhuis JW et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999;17:150-157.
9. Blay JY, van Glabbeke M, Verweij J et al. Advanced soft-tissue sarcoma: A disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 2003;39:64-69.
10. Fata F, O'Reilly E, Ilson D et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999;86:2034-2037.
11. Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007;25:2755-2763.
12. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol 2005;23:576-584.
13. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: A retrospective study. Lancet Oncol 2007;8:595-602.
14. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
15. Verweij J, Casali P, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004;364:1127-1134.
16. Maki RG, Awan RA, Dixon RH et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002;100:623-626.
17. Blay JY, El Sayadi H, Thiesse P et al. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol 2008 Feb 21 [Epub ahead of print].
18. Nielsen TO, West RB, Linn SC et al. Molecular characterisation of soft tissue tumours: A gene expression study. Lancet 2002;359:1301-1307.
19. Allander SV, Illei PB, Chen Y et al. Expression profiling of synovial sarcoma by cDNA microarrays: Association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 2002;161:1587-1595.
20. Nagayama S, Katagiri T, Tsunoda T et al. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res 2002;62:5859-5866.
21. Lee YF, John M, Edwards S et al. Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. Br J Cancer 2003;88:510-515.
22. Singletary SE, Williams NN, Rodeck U et al. Transforming growth factoralpha secretion by epidermal growth factor-dependent human tumor cell lines. Anticancer Res 1990;10:1501-1505.
23. Olayioye MA, Neve RM, Lane HA et al. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-3167.
24. Press MF, Lenz HJ. EGFR, HER2 and VEGF pathways: Validated targets for cancer treatment. Drugs 2007;67:2045-2075.
25. Willems SM, Schrage YM, Baelde JJ et al. Myxoid tumours of soft tissue: The so-called myxoid extracellular matrix is heterogeneous in composition. Histopathology 2008;52:465-474.
26. Van Glabbeke M, Verweij J, Judson I et al.; EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-549.
27. Saito T, Nagai M, Ladanyi M. SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: A potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. Cancer Res 2006;66:6919-6927.
28. Horvai AE, Kramer MJ, O'Donnell R. Beta-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: Atissue microarray study. Arch Pathol Lab Med 2006;130:792-798.
29. D'Arcy P, Maruwge W, Ryan BA et al. The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability. Mol Cancer Res 2008;6:127-138.
30. de Bruijn DR, van Dijk AH, Willemse MP et al. The C terminus of the synovial sarcoma-associated SSX proteins interacts with the LIM homeobox protein LHX4. Oncogene 2008;27:653-662.
31. Ishida M, Miyamoto M, Naitoh S et al. The SYT-SSX fusion protein down-regulates the cell proliferation regulator COM1 in t(x;18) synovial sarcoma. Mol Cell Biol 2007;27:1348-1355.
32. Kohno Y, Okamoto T, Ishibe T et al. Expression of claudin7 is tightly associated with epithelial structures in synovial sarcomas and regulated by an Ets family transcription factor, ELF3. J Biol Chem 2006;281:38941-38950.
33. de Bruijn DR, Allander SV, van Dijk AH et al. The synovial-sarcoma- associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. Cancer Res 2006;66:9474-9482.
34. Pretto D, Barco R, Rivera J et al. The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex. Oncogene 2006;25:3661-3669.
35. Watanabe T, Tsuda M, Makino Y et al. Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines. Mol Cancer Res 2006;4:499-510.
36. Törnkvist M, Natalishvili N, Xie Y et al. Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth. Biochem Biophys Res Commun 2008;368:793-800.
37. Barbashina, Benevenia J, Aviv H et al. Oncoproteins and proliferation markers in synovial sarcomas: A clinicopathologic study of 19 cases. J Cancer Res Clin Oncol 2002;128:610-616.
38. Bode B, Frigerio S, Behnke S et al. Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. Mod Pathol 2006;19:541-547.
39. Krsková L, Kalinová M, Brizová H et al. Molecular and immunohistochemical analysis of ERBB2 expression in correlation with proliferation rate in synovial sarcoma. Diagn Mol Pathol 2007;16:211-217.
40. Nuciforo PG, Pellegrini C, Fasani R et al. Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. Hum Pathol 2003;34:639-645.
41. Terry J, Lubieniecka JM, Kwan W et al. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. Clin Cancer Res 2005;11:5631-5638.